Tobin Juvenal Sells 1,730 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 1,730 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $28.25, for a total transaction of $48,872.50. Following the transaction, the insider owned 78,995 shares of the company’s stock, valued at approximately $2,231,608.75. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of CSTL opened at $30.40 on Thursday. The company has a market cap of $928.72 million, a price-to-earnings ratio of -46.06 and a beta of 0.98. Castle Biosciences, Inc. has a twelve month low of $17.72 and a twelve month high of $44.28. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $23.38 and a two-hundred day moving average of $26.23.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The firm had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. As a group, analysts predict that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Trending Headlines about Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The revised target indicates substantial potential upside and reflects confidence in Castle Biosciences’ diagnostic-testing growth outlook. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest quarterly results exceeded expectations, with revenue of $99.86 million versus the $86.23 million analyst consensus and a loss of $0.07 per share versus expectations for a $0.41 loss. The results support the case for improving operating performance, although the company remains unprofitable.
• Neutral Sentiment: Recent coverage highlighted developments involving Castle Biosciences’ diagnostics business, but the available details do not indicate whether the update will materially affect revenue, earnings or reimbursement expectations. Castle Biosciences diagnostics update
• Negative Sentiment: Multiple insiders disclosed stock sales totaling approximately $1.68 million. Derek J. Maetzold sold 28,646 shares, COO Kristen M. Oelschlager sold 8,586 shares, and Tobin W. Juvenal sold 19,040 shares in transactions conducted from July 31 through August 3. The sales reduced their holdings and may weigh on investor sentiment, particularly after the stock’s recent strength. However, all reported transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal than discretionary sales. Castle Biosciences insider sales filing

Analyst Ratings Changes

Several brokerages recently commented on CSTL. Zacks Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 26th. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. KeyCorp set a $35.00 price target on shares of Castle Biosciences in a report on Friday, May 29th. Canaccord Genuity Group lowered their price objective on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Finally, BTIG Research upped their target price on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.00.

Institutional Trading of Castle Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Federated Hermes Inc. purchased a new position in shares of Castle Biosciences during the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Castle Biosciences in the fourth quarter worth about $35,000. Jones Financial Companies Lllp boosted its stake in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Castle Biosciences by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after acquiring an additional 297 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Castle Biosciences by 63.7% during the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after acquiring an additional 976 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.